RO 6864018Alternative Names: RO-6864018
Latest Information Update: 01 Mar 2017
At a glance
- Originator Roche
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 11 Nov 2016 Adverse events, pharmacodynamic and pharmacokinetics data from a phase I trial in Hepatitis B presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
- 01 Feb 2015 Phase-II clinical trials in Hepatitis B (Treatment-experienced) in New Zealand (PO) (NCT02391805)
- 01 Nov 2014 Roche completes a phase I trial in Healthy volunteers in Singapore (NCT02015715)